Ascendis Pharma is committed to developing its own proprietary pipeline of unique products that meet unmet patient needs.
We have initiated the Phase 3 heiGHt Trial to evaluate daily TransCon Growth Hormone in children with GHD. To learn more about the phase 3 heiGHt Trial and receive future information, please visit: www.heighttrial.com.
Phase 3 heiGHt Trial Initiated
Our phase 3 clinical trial for TransCon Growth Hormone — the heiGHt Trial – has been initiated.